| Sophia Rey Pontello, | |
|
2500 S State St, South Salt Lake, UT 84115-3164 | |
| (385) 646-5000 | |
| Not Available |
| Full Name | Sophia Rey Pontello |
|---|---|
| Gender | Female |
| Speciality | Psychologist - School |
| Location | 2500 S State St, South Salt Lake, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376268094 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TS0200X | Psychologist - School | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sophia Rey Pontello, 550 N 300 W Unit 3308, Salt Lake City, UT 84103-2173 Ph: (315) 877-4103 | Sophia Rey Pontello, 2500 S State St, South Salt Lake, UT 84115-3164 Ph: (385) 646-5000 |
News Archive
"Nanotechnology could aid the future of development of the Arab region," says Mohamed H.A. Hassan, executive director of TWAS, the academy of sciences for the developing world, and president of the African Academy of Sciences. Hassan made his remarks at a panel session, "Re-emergence of Science, Technology and Education as Priorities in the Arab World," taking place at the AAAS's annual meeting in San Diego.
Senate Commerce, Science and Transportation Committee Chair Jay Rockefeller (D-W.Va.) on Tuesday will hold a hearing that follows lawsuits and an investigation by New York state Attorney General Andrew Cuomo (D) alleging that UnitedHealth Group and subsidiary Ingenix manipulated out-of-network rate data resulting in patients paying more for those services, the AP/USA Today reports.
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
In the August 12 issue of the journal Nature, researchers at the University of Pennsylvania detail the creation of a library of small protein-like molecules that can self-assemble to form hollow corkscrew-like pores that could mimic pores seen in living systems.
Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.
› Verified 7 days ago
Dr. Victoria Rose Hatton, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2500 S State St, South Salt Lake, UT 84115 Phone: 385-646-5000 | |
Nicole Feigt, ED.S, MS Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2500 S State St, South Salt Lake, UT 84115 Phone: 385-646-5000 | |
Mrs. Autumn Seraphina Talbott-cisneros, MS Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2500 S State St, South Salt Lake, UT 84115 Phone: 385-646-5000 | |
Chloe Ruebeck Marr, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2500 S State St, South Salt Lake, UT 84115 Phone: 385-646-8240 | |
Heather Elise Creel, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2500 S State St, South Salt Lake, UT 84115 Phone: 385-646-5000 | |
Taylor Jackson, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2500 S State St, South Salt Lake, UT 84115 Phone: 385-646-5000 | |
Bethany Sue Ortiz, EDS, NCSP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2500 S State St, South Salt Lake, UT 84115 Phone: 385-646-1641 |